Search

Your search keyword '"Govindarajan, Ameish"' showing total 161 results
Start Over Author "Govindarajan, Ameish"
161 results on '"Govindarajan, Ameish"'

1. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Author

Ebrahimi, Hedyeh, Dizman, Nazli, Meza, Luis, Malhotra, Jasnoor, Li, Xiaochen, Dorff, Tanya, Frankel, Paul, Llamas-Quitiquit, Marian, Hsu, Joann, Zengin, Zeynep B., Alcantara, Marice, Castro, Daniela, Mercier, Benjamin, Chawla, Neal, Chehrazi-Raffle, Alex, Barragan-Carrillo, Regina, Jaime-Casas, Salvador, Govindarajan, Ameish, Gillece, John, Trent, Jeffrey, Lee, Peter P., Parks, Thomas P., Takahashi, Motomichi, Hayashi, Atsushi, Kortylewski, Marcin, Caporaso, J. Gregory, Lee, Keehoon, Tripathi, Abhishek, and Pal, Sumanta K.

Published
2024
Full Text
View/download PDF

2. A Case of Disseminated Histoplasmosis From California, in the Setting of Secondary Hemophagocytic Lymphohistiocytosis: A Diagnostic Challenge

Author

Govindarajan, Ameish, Sous, Rowis, Venter, Frederick, Torrico, Tyler, Karapetians, Natalie, Heidari, Arash, Cobos, Everardo, and Petersen, Greti

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hematology, Infectious Diseases, Good Health and Well Being, Humans, Histoplasmosis, Lymphohistiocytosis, Hemophagocytic, Histoplasma, California, Histoplasma capsulatum, hemophagocytic lymphohistiocytosis, bilateral adrenal masses, fungus, dissemination, infectious disease
Abstract

Histoplasma capsulatum is a geographically specific dimorphic fungus that can cause a spectrum of diseases. While most cases are asymptomatic pulmonary infections, in severe cases, particularly in immunocompromised patients, disseminated disease can occur. Histoplasmosis in California is limited to only a few case reports. In this article, we describe a rare case of disseminated histoplasmosis in a non-endemic region presenting with diagnostically challenging symptomatology, including altered mental status, status epilepticus, septic shock, and bilateral adrenal masses.

Published
2023

4. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research

Author

Ebrahimi, Hedyeh, Castro, Daniela V., Feng, Matthew I., Prajapati, Sweta R., Lee, Kyle O., Chan, Elyse H., Paul, Trishita, Sehgal, Ishaan, Patel, Jalen, Li, Xiaochan, Zengin, Zeynep B., Meza, Luis, Mercier, Benjamin D., Hsu, JoAnn, Govindarajan, Ameish, Chawla, Neal, Dizman, Nazli, Bergerot, Cristiane D., Rock, Adam, Liu, Sandy, Tripathi, Abhishek, Dorff, Tanya, Pal, Sumanta K., and Chehrazi-Raffle, Alexander

Published
2023
Full Text
View/download PDF

6. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma

Author

Dizman, Nazli, Govindarajan, Ameish, Zengin, Zeynep B., Meza, Luis, Tripathi, Nishita, Sayegh, Nicolas, Castro, Daniela V., Chan, Elyse H., Lee, Kyle O., Prajapati, Sweta, Feng, Matthew, Loo, Vivian, Pace, Makala, O'Brien, Shea, Bailey, Erin, Barragan-Carrillo, Regina, Chehrazi-Raffle, Alex, Hsu, JoAnn, Li, Xiaochen, Agarwal, Neeraj, and Pal, Sumanta K.

Published
2023
Full Text
View/download PDF

13. Colorectal Carcinoma—An Anomalous Trigger of Adult Hemophagocytic Lymphohistiocytosis.

Author

Govindarajan, Ameish, Venter, Frederick, Chaudhry, Akriti, Kaur, Harsimranjit, Cobos, Everardo, and Petersen, Greti

Subjects
HEMOPHAGOCYTIC lymphohistiocytosis, HEMATOLOGIC malignancies, CHILD patients, COLORECTAL cancer, MULTIPLE organ failure
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare but often fatal condition characterized by a hyperinflammatory immune response leading to multiorgan failure. It is predominantly observed in the pediatric population and can be classified as familial or acquired HLH. The latter is more common in adults, often associated with malignancy, infection, or autoimmune diseases. Among acquired HLH cases, hematologic neoplasms account for the majority, with only a few isolated reports documenting solid neoplasms as the cause. Herein, we present a case of adult HLH associated with colorectal adenocarcinoma, which, to the best of our knowledge, is only the second reported case of HLH associated with this type of cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.

Author

Bergerot, Cristiane Decat, Philip, Errol J., Malhotra, Jasnoor, Bergerot, Paulo Gustavo, Castro, Daniela V., Govindarajan, Ameish, Salgia, Sabrina, Salgia, Meghan, Salgia, Nicholas, Hsu, JoAnn, Meza, Luis, Zengin, Zeynep B., Liu, Sandy, Chehrazi‐Raffle, Alex, Tripathi, Abhishek, Dorff, Tanya, and Pal, Sumanta

Abstract

We sought to determine racial and ethnic differences in perceptions (quality of communication, expectations, and concerns) of germline or somatic DNA sequencing (genomic profiling). Patients with prostate, urothelial, or kidney cancer were surveyed using a questionnaire that assessed previous experience, beliefs, expectations, and concerns regarding genomic profiling. Descriptive statistics and chi‐square tests were used to identify factors associated with patients' perceptions of genomic profiling. A total of 150 consecutive patients were enrolled. The majority were male (74%) with a mean age of 68 years old. Most patients underwent somatic testing (54%), 24% undertook germline testing, and 21% undertook both tests. Significant differences were found across racial and/or ethnicity concerning factors that could have influenced patients' decision to pursue genomic profiling, including ability to guide the type of treatment (White: 54.1% vs. other ethnic groups: 43.9%, p = 0.04) and potential to improve treatment response (White: 10.1% vs. other ethnic groups: 22.0%, p = 0.04). Other ethnic group of patients were more concerned about learning that the cancer was less treatable or aggressive (43.8% vs. 27.7%, p = 0.01) and anxious about what would be learnt from genomic profiling (34.4% vs. 21.3, p = 0.01) as compared to White patients. Our findings reinforce the importance of developing culturally tailored education to help patients participate actively in decisions about genomic profiling. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab

Author

Tripathi, Nishita, primary, Meza, Luis, additional, Sayegh, Nicolas, additional, Govindarajan, Ameish, additional, Byron, Sara A., additional, Zhang, Jiaming, additional, Chigarira, Beverly, additional, Jo, Yeonjung, additional, Zengin, Zeynep B., additional, Li, Haoran, additional, Gebrael, Georges, additional, Desai, Arpita, additional, Agarwal, Neeraj, additional, Swami, Umang, additional, Maughan, Benjamin L., additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

18. Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer

Author

Bergerot, Cristiane Decat, primary, Philip, Errol J., additional, Malhotra, Jasnoor, additional, Bergerot, Paulo Gustavo, additional, Castro, Daniela V., additional, Govindarajan, Ameish, additional, Salgia, Sabrina, additional, Salgia, Meghan, additional, Salgia, Nicholas, additional, Hsu, JoAnn, additional, Meza, Luis, additional, Zengin, Zeynep B., additional, Liu, Sandy, additional, Chehrazi‐Raffle, Alex, additional, Tripathi, Abhishek, additional, Dorff, Tanya, additional, and Pal, Sumanta, additional

Published
2023
Full Text
View/download PDF

19. CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)

Author

Ebrahimi, Hedyeh, primary, Lu, Kun-Han, additional, Castro, Daniela V, additional, Mercier, Benjamin D, additional, Dizman, Nazli, additional, Barragan-Carrillo, Regina, additional, Govindarajan, Ameish, additional, Meza, Luis, additional, Chawla, Neal S, additional, Hsu, JoAnn, additional, Chehrazi-Raffle, Alexander, additional, Tripathi, Abhishek, additional, Liu, Sandy, additional, Dorff, Tanya B, additional, Wah Wong, Chi, additional, Pal, Sumanta K, additional, and Zengin, Zeynep B, additional

Published
2023
Full Text
View/download PDF

20. The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Author

Castro, Daniela, primary, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Gebrael, Georges, additional, Li, Xiaochen, additional, Meza, Luis, additional, Zengin, Zeynep, additional, Chehrazi-Raffle, Alex, additional, Govindarajan, Ameish, additional, Dizman, Nazli, additional, Ebrahimi, Hedyeh, additional, Chawla, Neal, additional, Mercier, Benjamin, additional, Hsu BS, JoAnn, additional, Shi, Jessica, additional, Philip, Errol, additional, Bergerot, Cristiane, additional, Barragan-Carrillo, Regina, additional, and Pal, Sumanta, additional

Published
2023
Full Text
View/download PDF

21. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles

Author

Govindarajan, Ameish, primary, Salgia, Nicholas J., additional, Li, Haiqing, additional, Castro, Daniela V., additional, Mirzapoiazova, Tamara, additional, Armstrong, Brian, additional, Zhao, Dan, additional, Mercier, Benjamin D., additional, Dizman, Nazli, additional, Chawla, Neal, additional, Zengin, Zeynep, additional, Meza, Luis, additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Chehrazi-Raffle, Alex, additional, Tripathi, Abhishek, additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

22. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy

Author

Castro, Daniela V., primary, Prajapati, Sweta R., additional, Feng, Matthew I., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Paul, Trishita, additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, Li, Xiaochen, additional, Zengin, Zeynep B., additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Meza, Luis, additional, Mercier, Benjamin D., additional, Chawla, Neal S., additional, Dizman, Nazli, additional, Philip, Errol J., additional, Hsu, JoAnn, additional, Bergerot, Cristiane D., additional, Chehrazi‐Raffle, Alex, additional, Rock, Adam, additional, Liu, Sandy, additional, Tripathi, Abhishek, additional, Dorff, Tanya B., additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

23. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.

Author

Castro, Daniela V., Prajapati, Sweta R., Feng, Matthew I., Chan, Elyse H., Lee, Kyle O., Paul, Trishita, Sehgal, Ishaan, Patel, Jalen, Li, Xiaochen, Zengin, Zeynep B., Ebrahimi, Hedyeh, Govindarajan, Ameish, Meza, Luis, Mercier, Benjamin D., Chawla, Neal S., Dizman, Nazli, Philip, Errol J., Hsu, JoAnn, Bergerot, Cristiane D., and Chehrazi‐Raffle, Alex

Subjects
RENAL cell carcinoma, HEPATITIS C virus, HEPATITIS B virus, HIV, HIV infections
Abstract

Objectives: To characterise the restrictiveness of eligibility criteria in contemporary renal cell carcinoma (RCC) trials, using recommendations from the American Society of Clinical Oncology (ASCO)‐Friends of Cancer Research (FCR) initiative. Methods: vPhase I–III trials assessing systemic therapies in patients with RCC starting between 30 June 2012 and 30 June 2022 were identified. Eligibility criteria regarding brain metastases, prior or concurrent malignancies, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, and human immunodeficiency virus (HIV) infection were identified and stratified into three groups: exclusion, conditional inclusion, and not reported. Descriptive statistics were used to determine the frequency of eligibility criteria. Fisher's exact test or chi‐square test were used to calculate their associations with certain trial characteristics. Results: A total of 423 RCC trials were initially identified of which 112 (26.5%) had sufficient accessible information. Exclusion of patients with HIV infection, HBV/HCV infection, brain metastases, and prior or concurrent malignancies were reported in 74.1%, 53.6%, 33.0%, and 8.0% of trials, respectively. In the context of HIV and HBV/HCV infection, patients were largely excluded from trials evaluating immunotherapy (94.4% and 77.8%, respectively). In addition, brain metastases were excluded in trials assessing targeted therapy (36.4%), combined therapy (33.3%), and immunotherapy (22.2%). Exclusion of patients with prior or concurrent malignancies was less frequently reported, accounting for 9.1%, 8.3%, and 5.6% targeted therapy, combined therapy and immunotherapy trials, respectively. Conclusion: A substantial proportion of RCC trials utilise restrictive eligibility criteria, excluding patients with fairly prevalent comorbidities. Implementing the ASCO‐FCR recommendations will ensure resulting data are more inclusive and aligned with patient populations in the real‐world. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.

Author

Chawla, Neal Shiv, Mercier, Benjamin D., Govindarajan, Ameish, Li, Xiaochen, Castro, Daniela V., Ebrahimi, Hedyeh, Barragan-Carrillo, Regina, Zang, Peter D., LeVee, Alexis Ann, Dizman, Nazli, Hsu, Joann, Meza, Luis A, Zengin, Zeynep Busra, Salgia, Nicholas, Chehrazi-Raffle, Alex, Dorff, Tanya B., Pal, Sumanta Kumar, and Tripathi, Abhishek

Published
2024
Full Text
View/download PDF

25. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).

Author

Mercier, Benjamin D., Tripathi, Nishita, Govindarajan, Ameish, Gebrael, Georges, Narang, Arshit, Li, Xiaochen, Castro, Daniela V., Chehrazi-Raffle, Alex, Dizman, Nazli, Ebrahimi, Hedyeh, Chawla, Neal Shiv, Hsu, Joann, Bergerot, Cristiane Decat, Barragan-Carrillo, Regina, Zengin, Zeynep Busra, Meza, Luis A, Pal, Sumanta Kumar, Agarwal, Neeraj, and Tripathi, Abhishek

Published
2024
Full Text
View/download PDF

28. Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.

Author

Chehrazi-Raffle, Alexander, Leong, Sally, Ali, Sana, Kim, Tane, Melamed, Sam, Li, Xiaochen, Zengin, Zeynep, Meza, Luis, Chawla, Neal, Govindarajan, Ameish, Castro, Daniela, Mercier, Benjamin, Ebrahimi, Hedyeh, Dizman, Nazli, Tripathi, Nishita, Sayegh, Nicolas, Rock, Adam, Yeh, James, Pal, Sumanta K, and Onyshchenko, Mykola

Subjects
RENAL cell carcinoma, PATIENT aftercare, SPECIALTY hospitals, CONFIDENCE intervals, HISPANIC Americans, MULTIVARIATE analysis, HEALTH outcome assessment, METASTASIS, IPILIMUMAB, RETROSPECTIVE studies, REGRESSION analysis, CANCER patients, CANCER treatment, NIVOLUMAB, SAFETY-net health care providers, KAPLAN-Meier estimator, DESCRIPTIVE statistics, PROGRESSION-free survival, OVERALL survival, PROPORTIONAL hazards models, EVALUATION
Abstract

Background: There are limited data regarding the impact of ethnicity among patients receiving immune checkpoint inhibitors. We evaluated real-world outcomes between Latinx and non-Latinx patients with metastatic renal-cell carcinoma (mRCC) treated with first-line nivolumab/ipilimumab within 2 different healthcare settings. Methods: We performed a retrospective analysis of patients with mRCC who received nivolumab/ipilimumab within the Los Angeles County Department of Health Services (LAC-DHS), a safety-net healthcare system, and the City of Hope Comprehensive Cancer Center (COH), a tertiary oncology center, between January 1, 2015 and December 31, 2021. Progression-free survival (PFS) and overall survival (OS) were determined using the Kaplan-Meier method and covariates were adjusted using multivariate Cox proportional hazards regression. Results: Of 94 patients, 40 patients (43%) were Latinx while the remainder were non-Latinx (44 pts [46%] White, 7 pts [7%] Asian, and 3 pts [3%] Other). Fifty (53%) and 44 (47%) patients received their care at COH and LAC-DHS, respectively. Most Latinx patients (95%) were treated at LAC-DHS, and most non-Latinx patients (89%) were treated at COH. Pooled analysis by ethnicity demonstrated significantly shorter PFS in Latinx versus non-Latinx patients (10.1 vs. 25.2 months, hazard ratios [HR] 3.61, 95% CI 1.96-6.66, P ≤.01). Multivariate analysis revealed a HR of 3.41 (95% CI 1.31-8.84; P =.01). At a median follow-up of 11.0 months, the median OS was not reached in either arm at the time of data cutoff. Conclusion: Latinx patients with mRCC had a shorter PFS treated with frontline nivolumab/ipilimumab compared to their non-Latinx counterparts. No difference was observed in OS although these data were immature. Larger studies are needed to further interrogate the social and economic determinants of ethnicity on clinical outcomes in mRCC. This article evaluates real-world outcomes between Latinx and non-Latinx patients with metastatic renal-cell carcinoma treated with first-line nivolumab/ipilimumab within 2 different healthcare settings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).

Author

Leong, Sally, primary, Ali, Sana, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Dizman, Nazli, additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Li, Xiaochen, additional, Kim, Tane, additional, Melamed, Sam, additional, Onyshchenko, Mykola, additional, Pal, Sumanta Monty, additional, and Chehrazi-Raffle, Alex, additional

Published
2023
Full Text
View/download PDF

31. Impact of race and payer status on the choice of urinary diversion among patients with localized bladder carcinoma undergoing cystectomy.

Author

Tripathi, Abhishek, primary, Barragan-Carrillo, Regina, additional, Philip, Errol James, additional, Govindarajan, Ameish, additional, Chawla, Neal, additional, Castro, Daniela V., additional, Chehrazi-Raffle, Alexander, additional, Dizman, Nazli, additional, Hsu, Joann, additional, Meza, Luis A, additional, Zengin, Zeynep Busra, additional, Bergerot, Cristiane Decat, additional, Eilber, Karyn, additional, Pal, Sumanta Monty, additional, and Dallas, Kai, additional

Published
2023
Full Text
View/download PDF

32. Improved health-related quality of life (HR-QOL) with use of an online mindfulness tool in patients with metastatic renal cell carcinoma (mRCC) receiving immunotherapy (IO).

Author

Bergerot, Cristiane Decat, primary, Malhotra, Jasnoor, additional, Bergerot, Paulo Gustavo, additional, Philip, Errol James, additional, Castro, Daniela V., additional, Govindarajan, Ameish, additional, Molina, Lorena Nascimento Manrique, additional, Fuzita, William Hiromi, additional, Azeredo, Andressa Cardoso, additional, Mota, Augusto C. A., additional, Franca, Marcos V S, additional, Anjos, Gabriel dos, additional, Filho, Romildo De Araujo Periera, additional, de Souza, Douglas Manfroi, additional, Hsu, Joann, additional, Chawla, Neal, additional, Chehrazi-Raffle, Alex, additional, Saab, Bechara, additional, Carlson, Linda E, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

33. Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC).

Author

Barragan-Carrillo, Regina, primary, Dallas, Kai, additional, Tripathi, Abhishek, additional, Govindarajan, Ameish, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Philip, Errol James, additional, Castro, Daniela V., additional, Chehrazi-Raffle, Alexander, additional, Chawla, Neal, additional, Hsu, Joann, additional, Dizman, Nazli, additional, Eilber, Karyn, additional, Bergerot, Cristiane Decat, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

34. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).

Author

Chehrazi-Raffle, Alex, primary, Tukachinsky, Hanna, additional, Schrock, Alexa Betzig, additional, Hwang, Justin, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Chawla, Neal Shiv, additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Rock, Adam, additional, Tripathi, Abhishek, additional, Dorff, Tanya B., additional, Pal, Sumanta Monty, additional, Oxnard, Geoffrey R., additional, Agarwal, Neeraj, additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

35. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).

Author

Dizman, Nazli, primary, Govindarajan, Ameish, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Castro, Daniela V., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Prajapati, Sweta R., additional, Feng, Matthew I., additional, Loo, Vivian, additional, Pace, Makala, additional, O'brien, Shea, additional, Bailey, Erin B., additional, Barragan-Carrillo, Regina, additional, Chehrazi-Raffle, Alex, additional, Li, Xiaochen, additional, Agarwal, Neeraj, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

36. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).

Author

Ebrahimi, Hedyeh, primary, Battle, Dena, additional, Zengin, Zeynep Busra, additional, Dizman, Nazli, additional, Meza, Luis A, additional, Castro, Daniela V., additional, Govindarajan, Ameish, additional, Mercier, Benjamin D., additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Tripathi, Abhishek, additional, Liu, Sandy, additional, Vaishampayan, Ulka N., additional, Staehler, Michael D., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

37. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors

Author

Chawla, Neal S., primary, Sayegh, Nicolas, additional, Tripathi, Nishita, additional, Govindarajan, Ameish, additional, Zengin, Zeynep B., additional, Phillip, Errol J., additional, Dizman, Nazli, additional, Meza, Luis, additional, Muddasani, Ramya, additional, Chehrazi-Raffle, Alexander, additional, Malhotra, Jasnoor, additional, Hsu, JoAnn, additional, Agarwal, Neeraj, additional, Pal, Sumanta K., additional, and Tripathi, Abhishek, additional

Published
2023
Full Text
View/download PDF

38. Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study

Author

Castro, Daniela V., primary, Zengin, Zeynep B., additional, Malhotra, Jasnoor, additional, Bergerot, Cristiane D., additional, Meza, Luis, additional, Dizman, Nazli, additional, Govindarajan, Ameish, additional, Hsu, JoAnn, additional, Chehrazi-Raffle, Alex, additional, Chawla, Neal, additional, Mercier, Benjamin D., additional, Chen, Sean W., additional, Feng, Matthew, additional, Prajapati, Sweta, additional, Lee, Kyle O., additional, Philip, Errol J., additional, Dorff, Tanya B., additional, Lyou, Yung, additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

40. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma

Author

Zengin, Zeynep B., primary, Govindarajan, Ameish, additional, Salgia, Nicholas, additional, Sayegh, Nicolas, additional, Tripathi, Nishita, additional, Muddasani, Ramya, additional, Chehrazi-Raffle, Alex, additional, Feng, Matthew, additional, Mercier, Benjamin D., additional, Ladbury, Colton, additional, Hao, Claire, additional, Salgia, Sabrina, additional, Chawla, Neal, additional, Meza, Luis, additional, Malhotra, Jasnoor, additional, Dizman, Nazli, additional, Hsu, JoAnn, additional, Castro, Daniela V., additional, Barragan-Carrillo, Regina, additional, Ebrahimi, Hedyeh, additional, Philip, Errol J., additional, Chang, Mark, additional, Zhang, Jiaming, additional, Byron, Sara, additional, Lyou, Yung, additional, Dorff, Tanya, additional, Pal, Sumanta K., additional, and Dandapani, Savita, additional

Published
2023
Full Text
View/download PDF

41. 880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC)

Author

Chehrazi-Raffle, Alexander, primary, Alcantara, Marice, additional, Dizman, Nazli, additional, Tang, Wilson, additional, Meza, Luis, additional, Zengin, Zeynep, additional, Wang, Dongfang, additional, Moreira, Dayson, additional, Castro, Daniela, additional, Govindarajan, Ameish, additional, Horsager, Alan, additional, Hsu, JoAnn, additional, Pal, Sumanta, additional, and Kortylewski, Marcin, additional

Published
2022
Full Text
View/download PDF

42. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.

Author

Meza, Luis, Zengin, Zeynep, Salgia, Sabrina, Malhotra, Jasnoor, Karczewska, Ewa, Dorff, Tanya, Tripathi, Abhishek, Ely, Jennifer, Kelley, Erin, Mead, Heather, Hsu, JoAnn, Dizman, Nazli, Salgia, Nicholas, Chawla, Neal, Chehrazi-Raffle, Alex, Muddasani, Ramya, Govindarajan, Ameish, Rock, Adam, Liu, Sandy, and Salgia, Ravi

Subjects
RENAL cell carcinoma, PATIENT aftercare, IMMUNIZATION, IMMUNOGLOBULINS, CONFIDENCE intervals, COVID-19 vaccines, GENITOURINARY organ tumors, SEROCONVERSION, CANCER patients, T-test (Statistics), IMMUNITY, ENZYME-linked immunosorbent assay, T cells, ODDS ratio, PROSTATE tumors
Abstract

Background: Vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have had a transformative impact on morbidity and mortality. However, the long-term impact of vaccination on patients with genitourinary cancers is currently unknown. Materials and Methods: This study aimed to assess seroconversion rates in patients with genitourinary cancers receiving COVID-19 vaccination. Patients with prostate cancer, renal cell carcinoma, or urothelial cancer who had not been vaccinated for COVID-19 were included. Blood samples were obtained at baseline and after 2, 6, and 12 months of one dose of an FDA-approved COVID-19 vaccine. Antibody titer analysis was performed using the SCoV-2 Detect IgG ELISA assay, and the results were reported as immune status ratio (ISR). A paired t-test was used for comparison of ISR values between timepoints. In addition, T-cell receptor (TCR) sequencing was performed to assess for differences in TCR repertoire 2 months after vaccination. Results: Out of 133 patients enrolled, 98 baseline blood samples were collected. At 2-, 6-, and 12-month time points 98, 70, and 50 samples were collected, respectively. Median age was 67 (IQR, 62-75), with the majority of patients diagnosed with prostate (55.1%) or renal cell carcinoma (41.8%). Compared to baseline (0.24 [95% CI, 0.19-0.31]) a significant increase in the geometric mean ISR values was observed at the 2-month timepoint (5.59 [4.76-6.55]) (P <.001). However, at the 6-month timepoint, a significant decrease in the ISR values was observed (4.66 [95% CI, 4.04-5.38]; P <.0001). Notably, at the 12-month timepoint, the addition of a booster dose resulted in an absolute increase in the ISR values compared to those who did not receive a booster dose (P =.04). Conclusions: Only a minority of patients with genitourinary cancers did not ultimately achieve satisfactory seroconversion after receiving commercial COVID-19 vaccination. Cancer type or treatment rendered did not appear to affect the immune response mounted after vaccination. The long-term effect of vaccination against SARS-CoV-2 on patients with genitourinary cancers is currently unknown. This study assessed the long-term effect of commercially available COVID-19 vaccination in patients with renal cell carcinoma, urothelial carcinoma, and prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Abstract 6293: Genomic characteristics of nivolumab/ipilimumab with or without CBM-588 supplementation in patients with metastatic renal cell carcinoma

Author

Castro, Daniela V., primary, Dizman, Nazli, additional, Zengin, Zeynep B., additional, Malhotra, Jasnoor, additional, Meza, Luis A., additional, Muddasani, Ramya, additional, Govindarajan, Ameish, additional, Chawla, Neal S., additional, Chehrazi-Raffle, Alex, additional, Hsu, JoAnn, additional, Bergerot, Paulo G., additional, Bergerot, Cristiane D., additional, Dorff, Tanya B., additional, Lyou, Yung, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

45. Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.

Author

Dizman, Nazli, primary, Meza, Luis A, additional, Bergerot, Paulo Gustavo, additional, Dorff, Tanya B., additional, Lyou, Yung, additional, Frankel, Paul Henry, additional, Llamas, Marian, additional, Hsu, Joann, additional, Zengin, Zeynep Busra, additional, Malhotra, Jasnoor, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Gillece, John D, additional, Reining, Lauren J, additional, Trent, Jeffrey M., additional, Takahashi, Motomichi, additional, Oka, Kentaro, additional, Higashi, Seiya, additional, Highlander, Sarah K, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

46. A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).

Author

Meza, Luis A, primary, Malhotra, Jasnoor, additional, Zengin, Zeynep Busra, additional, Dizman, Nazli, additional, Hsu, Joann, additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Muddasani, Ramya, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Dorff, Tanya B., additional, Lyou, Yung, additional, Frankel, Paul Henry, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

47. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).

Author

Zengin, Zeynep Busra, primary, Govindarajan, Ameish, additional, Muddasani, Ramya, additional, Salgia, Nicholas, additional, Sayegh, Nicolas, additional, Tripathi, Nishita, additional, Salgia, Sabrina, additional, Meza, Luis A, additional, Zhang, Jiaming, additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Malhotra, Jasnoor, additional, Dizman, Nazli, additional, Hsu, Joann, additional, Castro, Daniela V., additional, Byron, Sara A., additional, Dandapani, Savita V., additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

50. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.

Author

Malhotra, Jasnoor, primary, Philip, Errol James, additional, Govindarajan, Ameish, additional, Meza, Luis A, additional, Zengin, Zeynep Busra, additional, Salgia, Sabrina, additional, Muddasani, Ramya, additional, Chawla, Neal Shiv, additional, Castro, Daniela, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Bergerot, Paulo Gustavo, additional, Hsu, Joann, additional, Dorff, Tanya B., additional, Pal, Sumanta K., additional, and Bergerot, Cristiane Decat, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results